[doi:10.1063/1.3536794]“
“Two new secoiridoid glycosides, oleuricines A (1) and B (2), together with five known triterpenoids, beta-amyrin, oleanolic acid, erythrodiol,

urs-2 beta,3 beta-dihydroxy-12-en-28-oic acid, and beta-maslinic acid, were isolated from the EtOAc-soluble part of EtOH extract of the leaves of Olea europaea L. The structures of these compounds were elucidated by various spectroscopic methods, including intensive 1D, 2D NMR, and HR-ESI-MS techniques.”
“EmsB is a molecular marker applied to Echinococcus multilocularis genotyping studies. This marker has largely been used to investigate the epidemiology of the parasite in different endemic foci. The present study has lifted the veil on the genetic structure of this microsatellite.

By in silico analysis on the E. multilocularis genome the microsatellite was described in about 40 copies on the Repotrectinib price chromosome Fedratinib 5 of the parasite. Similar structure was found in the relative parasite Echinococcus granulosus, where the microsatellite was firstly described. The present study completes the first investigations made on the EmsB microsatellite origins and confirms the reliability of this highly discriminant molecular marker. (C) 2015 Elsevier B.V. All rights reserved.”
“Objective: The purpose of this study was to assess outcomes and indications in a large cohort of patients who underwent liver transplantation (LT) for liver metastases (LM) from neuroendocrine tumors (NET) over a 27-year period.\n\nBackground: LT for NET remains controversial due to the absence of clear selection criteria and the scarcity and heterogeneity of reported cases.\n\nMethods: Etomoxir inhibitor This retrospective multicentric study included 213 patients who underwent LT for NET performed in 35 centers in 11 European countries between 1982 and 2009. One hundred seven patients underwent transplantation before 2000 and 106 after 2000. Mean age at the time of LT was 46 years. Half of the patients presented hormone secretion and 55% had hepatomegaly. Before LT, 83% of patients had undergone surgical treatment of the primary

tumor and/or LM and 76% had received chemotherapy. The median interval between diagnosis of LM and LT was 25 months (range, 1-149 months). In addition to LT, 24 patients underwent major resection procedures and 30 patients underwent minor resection procedures.\n\nResults: Three-month postoperative mortality was 10%. At 5 years after LT, overall survival (OS) was 52% and disease-free survival was 30%. At 5 years from diagnosis of LM, OS was 73%. Multivariate analysis identified 3 predictors of poor outcome, that is, major resection in addition to LT, poor tumor differentiation, and hepatomegaly. Since 2000, 5-year OS has increased to 59% in relation with fewer patients presenting poor prognostic factors. Multivariate analysis of the 106 cases treated since 2000 identified the following predictors of poor outcome: hepatomegaly, age more than 45 years, and any amount of resection concurrent with LT.